Final overall study analysis continues to show benefit of sacituzumab govitecan in advanced HR+ breast cancer

by

A novel antibody-drug conjugate continues to demonstrate superior benefit for patients with HR+, HER2- metastatic breast cancer when compared to standard chemotherapy, according to a new study in The Lancet.

Leave A Comment

Your email address will not be published. Required fields are marked *